What Happened?

Shares of digital medical services platform Teladoc Health (NYSE: TDOC) jumped 3.5% in the afternoon session after the company received a price target increase from an analyst at Evercore ISI Group. Evercore ISI analyst Elizabeth Anderson raised the firm's price target on the virtual healthcare company to $8.00 from $7.00, while maintaining an "In-Line" rating on the shares. 

An "In-Line" rating suggests the analyst expects the stock to perform in line with the broader market. While not a full-fledged upgrade, the higher price target indicates a slightly more positive valuation outlook from the analyst.

After the initial pop the shares cooled down to $8.78, up 3.1% from previous close.

Is now the time to buy Teladoc? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Teladoc’s shares are extremely volatile and have had 43 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

Teladoc is down 7.8% since the beginning of the year, and at $8.78 per share, it is trading 38.8% below its 52-week high of $14.33 from February 2025. Investors who bought $1,000 worth of Teladoc’s shares 5 years ago would now be looking at an investment worth $38.41.

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.